Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.
Vet Comp Oncol. 2013 Dec;11(4):306-15. doi: 10.1111/j.1476-5829.2012.00324.x. Epub 2012 May 2.
Dose intense CHOP protocols have been shown to improve outcome for people with non-Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Thirty-one client owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression-free interval (PFI) of 140 days [95% confidence interval (CI) 91-335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.
大剂量 CHOP 方案已被证明可改善非霍奇金淋巴瘤患者的预后，但目前对犬淋巴瘤大剂量 CHOP 方案的评估有限。本回顾性研究的假设是，15 周的大剂量 CHOP 方案的治疗持续时间更短，与其他基于多柔比星的多药物方案的疗效相当。31 只患有多中心淋巴瘤的患犬接受了 15 周的 CHOP 化疗方案治疗，总有效率为 100%，无进展生存期（PFI）中位数为 140 天[95%置信区间（CI）91-335 天]。在多变量分析中，有两次或更多次治疗延迟的犬 PFI 和总生存期显著延长。剂量强度与患者预后无关。由于不良反应而多次延迟治疗的犬可能会接受个体最大耐受剂量，而无不良反应的犬可能会剂量不足。未来的研究应侧重于个体化患者剂量优化。
